Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Duaklir Genuair 340 micrograms /12 micrograms inhalation powder

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Aclidinium bromide, Formoterol fumarate dihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Aclidinium bromide, Formoterol fumarate dihydrate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

What Duaklir Genuair is This medicine contains two active ingredients called aclidinium and formoterol fumarate dihydrate. Both belong to a group of medicines called bronchodilators. Bronchodilators relax the muscles in your airways, which allows the airways to open more widely and helps you to breathe more easily. The Genuair inhaler delivers the active ingredients directly into your lungs as you breathe in. What Duaklir Genuair is used for Duaklir Genuair is used for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD), in which the airways and air sacs in the lungs become damaged or blocked. By opening the airways, the medicine helps relieve symptoms such as shortness of breath. Taking Duaklir Genuair regularly will reduce the effects of COPD on your everyday life. 2.

What you need to know before you take it

e Duaklir Genuair

Do not use Duaklir Genuair:

  • if you are allergic to aclidinium, formoterol fumarate dihydrate or to the other ingredient of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Duaklir Genuair, if you have any of the following conditions/symptoms: If you have asthma. This medicine should not be used for the treatment of asthma. If you have heart problems. If you have epilepsy. If you have thyroid gland problems (thyrotoxicosis). If you have a tumour in one of your adrenal glands (phaeochromocytoma). If you have difficulty passing urine or problems due to an enlarged prostate. If you have an eye condition called narrow angle glaucoma, which results in high pressure in the eye.

Confidential

Stop taking Duaklir Genuair and seek medical help immediately if you experience any of the following:

  • If you get sudden tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. See section 4. Duaklir Genuair is used as a maintenance (long-term) treatment for COPD. You should not use this medicine to treat a sudden attack of breathlessness or wheezing. If your usual COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse while you are using Duaklir Genuair you should continue to use it, but go to see your doctor as soon as possible because you may need another medicine. If you see halos around lights or coloured images, have eye pain or discomfort or suffer temporary blurring of vision, go to see your doctor for advice as soon as possible. Dry mouth has been observed with medicines like Duaklir Genuair. In the long-term, dry mouth can be associated with tooth decay, so it is important to pay attention to oral hygiene. Children and adolescents Duaklir Genuair is not for use in children or adolescents below 18 years of age. Other medicines and Duaklir Genuair Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. If you use Duaklir Genuair with some other medicines, the effect of Duaklir Genuair or the other medicines may be altered. Tell your doctor or pharmacist if you are taking:
  • Any medicines that may be similar to Duaklir Genuair to treat breathing difficulties.
  • Medicines that lower the amount of potassium in your blood. These include: o corticosteroids that you take by mouth (such as prednisolone), o diuretics (such as furosemide or hydrochlorothiazide), o certain medicines used to treat breathing conditions (such as theophylline).
  • Medicines called beta blockers that may be used to treat high blood pressure or other heart problems (such as atenolol or propranolol) or to treat glaucoma (such as timolol).
  • Medicines which can cause a type of change in the electrical activity of the heart known as QT interval prolongation (observed in an electrocardiogram). These include medicines for the treatment of: o depression (such as monoamine oxidase inhibitors or tricyclic antidepressants), o bacterial infections (such as erythromycin, clarithromycin, telithromycin), o allergic reactions (anti-histamines). Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before using this medicine. You should not use Duaklir Genuair if you are pregnant or are breast-feeding unless your doctor tells you to do so. Driving and using machines Duaklir Genuair is unlikely to affect your ability to drive or use machines. In some patients, this medicine may cause blurred vision or dizziness. If you are affected by either of these side effects, do not drive or use machines until the dizziness has cleared or your vision has returned to normal. Duaklir Genuair contains lactose This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 3.

How to take it

Duaklir Genuair

Confidential

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. –

–

The recommended dose is one inhalation in the morning and one inhalation in the evening. You can use Duaklir Genuair anytime before or after food or drink. The effects of Duaklir Genuair last for 12 hours; therefore, you should try to use Duaklir Genuair at the same time each morning and evening as this will ensure that there is always enough medicine in your body to help you breathe more easily throughout the day and night. Taking your medicine at regular times will also help you to remember to use it. The recommended dose can be used for elderly patients and for patients with kidney or liver problems. No dose adjustments are necessary in these patients. Duaklir Genuair is for inhalation use. Instructions for use: Refer to the Instructions for Use at the end of this leaflet for instructions on how to use the Genuair inhaler. If you are not sure of how to use Duaklir Genuair, contact your doctor or pharmacist.

COPD is a long-term disease; therefore, Duaklir Genuair is for long-term use. The medicine must be used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced. If you use more Duaklir Genuair than you should If you think you may have used more Duaklir Genuair than you should, you are more likely to experience some of its side effects, such as blurred vision, dry mouth, feeling sick, shaking/tremor, headache, palpitations or an increase in blood pressure, therefore you must immediately contact your doctor or go to the nearest emergency unit. Show the packaging of Duaklir Genuair. Medical attention may be needed. If you forget to use Duaklir Genuair If you forget a dose of Duaklir Genuair, just take it as soon as possible and take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose. If you stop using Duaklir Genuair This medicine is for long-term use. If you want to stop treatment, first talk to your doctor, as your symptoms may worsen. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop using the medicine and contact your doctor immediately if you: –

develop swelling of the face, throat, lips or tongue (with or without difficulty breathing or swallowing), severe itchy bumps on the skin (hives) as these may be symptoms of an allergic reaction. Frequency of this reaction cannot be estimated from the available data. develop tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. These may be signs of a condition called "paradoxical bronchospasm", which is an excessive and prolonged contraction of the airway muscles immediately following treatment with a bronchodilator. This reaction may rarely occur (may affect up to 1 in 1,000 people).

Some side effects may be serious: if you get any of these side effects, tell your doctor immediately. Uncommon (may affect up to 1 in 100 people)

  • Muscle weakness, twitching and/or abnormal heart rhythm, as these may be signs of a decrease in the amount of potassium in your blood

Confidential

–

Tiredness, increased thirst and/or a need to pass urine more frequently than usual, as these may be signs of an increase in the amount of sugar in your blood Palpitations, as these may be a sign of an unusually fast heart beat or an abnormal heart rhythm

Rare (may affect up to 1 in 1,000 people)

  • Sudden difficulty in breathing or swallowing, swelling of the tongue, throat, lips or face, skin rash and/or itching – these may be signs of an allergic reaction Other side effects which may occur while using Duaklir Genuair: Common (may affect up to 1 in 10 people)
  • Combination of sore throat and runny nose – these may be signs of nasopharyngitis
  • Headache
  • Painful and/or frequent urination – these may be signs of a urinary tract infection
  • Cough
  • Diarrhoea
  • A blocked, runny or stuffy nose and/or pain or a feeling of pressure in the cheeks or forehead – these may be symptoms of sinusitis
  • Dizziness
  • Muscle cramps
  • Nausea (feeling sick)
  • Difficulty sleeping
  • Dry mouth
  • Muscle pain
  • Abscess (infection) in the tissues at the base of a tooth
  • Increased blood levels of a protein found in muscle called creatine phosphokinase
  • Shaking/tremor
  • Anxiety Uncommon
  • Fast heart beat (tachycardia)
  • Abnormal or irregular heartbeat (cardiac arrhythmias)
  • Chest pain or tightness in the chest (angina pectoris)
  • Blurred vision
  • Changes in the sound of the voice (dysphonia)
  • Difficulty passing urine or a feeling that your bladder has not completely emptied (urinary retention)
  • An abnormal heart trace (QT interval prolongation) potentially leading to an abnormal heart rhythm
  • Distorted sense of taste (dysgeusia)
  • Throat irritation
  • Inflammation of the mouth (stomatitis)
  • Increased blood pressure
  • Agitation
  • Rash
  • Itching of the skin Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Duaklir Genuair

Confidential

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the inhaler label, carton and inhaler bag after "EXP". The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Keep the Genuair inhaler protected inside the sealed bag until the administration period starts. To be used within 60 days of opening the bag. Do not use Duaklir Genuair if you notice that the pack is damaged or shows signs of tampering. After you have taken the last dose, the inhaler has to be disposed of. Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Duaklir Genuair contains The active substances are aclidinium and formoterol fumarate dihydrate. Each delivered dose (the dose leaving the mouthpiece) contains 396 micrograms aclidinium bromide equivalent to 340 micrograms of aclidinium and 11.8 micrograms of formoterol fumarate dihydrate. The other ingredient is lactose monohydrate (see end of section 2 under 'Duaklir Genuair contains lactose' for more information). What Duaklir Genuair looks like and contents of the pack Duaklir Genuair is a white or almost white inhalation powder. The Genuair inhaler is a white device fitted with an integral dose indicator and an orange dosage button. The mouthpiece is covered with a removable orange protective cap. It is supplied in a sealed protective aluminium bag containing a desiccant sachet. After removing the inhaler from the bag, the bag and desiccant sachet should be thrown away. Pack sizes supplied: Carton containing 1 inhaler with 30 doses. Carton containing 1 inhaler with 60 doses. Carton containing 3 inhalers each with 60 doses. Not all pack sizes may be marketed. Marketing Authorisation Holder Azurity Pharmaceuticals Ireland Ltd. The Observatory 7-11 Sir John Rogerson's Quay Dublin 2, D02 VC42 Ireland Manufacturer Industrias Farmacéuticas Almirall, S.A. Ctra. de Martorell 41-61 08740 Sant Andreu de la Barca, Barcelona Spain This leaflet was last revised in July 2026.

Confidential

Other sources of information

To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 08004334029 (UK only) Please be ready to give the following information: Product name Duaklir Genuair 340 micrograms / 12 micrograms inhalation powder

Reference number PL 60277/0003

This is a service provided by the Royal National Institute of the Blind. Instructions for Use This section contains information on how to use your Genuair inhaler. It is important that you read this information as the Genuair may work differently from inhalers you have used previously. If you have any questions about how to use your inhaler, please ask your doctor, pharmacist or nurse for assistance. The Instructions for Use is divided into the following sections:

  • Getting started
  • Step 1: Prepare your dose
  • Step 2: Inhale your medicine
  • Additional information Getting Started Read these Instructions for Use before you start using the medicine. Become familiar with the parts of your Genuair inhaler.

Confidential

Control window Green = inhaler ready to use

Dose indicator

Protective Cap

Orange button

Control window Red = confirms correct inhalation

Mouthpiece

Figure A Before use: a) Before first use, tear open the sealed bag and remove the inhaler. Throw away the bag and the desiccant. b) Do not press the orange button until you are ready to take a dose. c) Pull off the cap by lightly squeezing the arrows marked on each side (Figure B).

Squeeze here and pull

Figure B STEP 1: Prepare your dose 1.1 Look in the opening of the mouthpiece and make sure nothing is blocking it (Figure C). 1.2 Look at the control window (should be red, Figure C).

Confidential

RED

Check mouthpiece opening

Figure C 1.3 Hold the inhaler horizontally with the mouthpiece facing you and the orange button on top (Figure D).

Figure D 1.4 Press the orange button all the way down to load your dose (Figure E). When you press the button all the way down, the control window changes from red to green. Make sure the orange button is on top. Do not tilt. 1.5 Release the orange button (Figure F). Make sure you release the button so the inhaler can work correctly.

Figure E

Figure F

Confidential

Stop and Check: 1.6 Make sure the control window is now green (Figure G). Your medicine is ready to be inhaled. Go to 'STEP 2: Inhale your medicine'. GREEN

Figure G What to do if the control window is still red after pressing the button (Figure H).

Figure H The dose is not prepared. Go back to 'STEP 1 Prepare your dose' and repeat steps 1.1 to 1.6. STEP 2: Inhale your medicine Read steps 2.1 to 2.7 fully before use. Do not tilt. 2.1 Hold the inhaler away from your mouth, and breathe out completely. Never breathe out into the inhaler (Figure I).

Figure I

Confidential

2.2 Hold your head upright, put the mouthpiece between your lips, and close your lips tightly around it (Figure J). Do not hold the orange button down while inhaling.

Figure J 2.3 Take a strong, deep breath through your mouth. Keep breathing in for as long as possible. A 'click' will let you know that you are inhaling correctly. Keep breathing in as long as possible after you hear the 'click'. Some patients may not hear the 'click'. Use the control window to ensure you have inhaled correctly. 2.4 Take the inhaler out of your mouth. 2.5 Hold your breath for as long as possible. 2.6 Slowly breathe out away from the inhaler. Some patients may experience a grainy sensation in their mouth, or a slightly sweet or bitter taste. Do not take an extra dose even if you do not taste or feel anything after inhaling. Stop and Check: 2.7 Make sure the control window is now red (Figure K). This means you have inhaled your medicine correctly. RED

Figure K

Confidential

What to do if the control window is still green after inhalation (Figure L).

Figure L This means you have not inhaled your medicine correctly. Go back to 'STEP 2 Inhale your medicine' and repeat steps 2.1 to 2.7. If the control window still does not change to red, you may have forgotten to release the orange button before inhaling, or you may not have inhaled strongly enough. If this happens, try again. Make sure you have released the orange button, and you have breathed out completely. Then take a strong, deep breath through the mouthpiece. Please contact your doctor if the control window is still green after repeated attempts. Push the protective cap back onto the mouthpiece after each use (Figure M), to prevent contamination of the inhaler with dust or other materials. You should discard your inhaler if you lose the cap.

Figure M Additional information What should you do if you accidently prepare a dose? Store your inhaler with the protective cap in place until it is time to inhale your medicine, then remove the cap and start at Step 1.6. How does the dose indicator work?

  • The dose indicator shows the total number of doses left in the inhaler (Figure N).
  • On first use, every inhaler contains at least 60 doses, or at least 30 doses, depending on the pack size.
  • Each time you load a dose by pressing the orange button, the dose indicator moves by a small amount towards the next number (50, 40, 30, 20, 10, or 0). When should you get a new inhaler? You should get a new inhaler:
  • If your inhaler appears to be damaged or if you lose the cap, or

Confidential

  • When a red band appears in the dose indicator, this means you are nearing your last dose (Figure N), or
  • If your inhaler is empty (Figure O). Dose indicator moves slowly from 60 to 0: 60, 50, 40, 30, 20, 10, 0. Dose indicator

Red band

Figure N How do you know that your inhaler is empty? When the orange button will not return to its full upper position and is locked in a middle position, you have reached the last dose (Figure O). Even though the orange button is locked, your last dose may still be inhaled. After that, the inhaler cannot be used again and you should start using a new inhaler.

Locked

Figure O How should you clean the inhaler? NEVER use water to clean the inhaler, as this may damage your medicine. If you wish to clean your inhaler, just wipe the outside of the mouthpiece with a dry tissue or paper towel.

Confidential

Frequently asked questions about Duaklir Genuair 340 micrograms /12 micrograms inhalation powder

How do I take Duaklir Genuair 340 micrograms /12 micrograms inhalation powder?

Duaklir Genuair 340 micrograms /12 micrograms inhalation powder comes as inhaler containing 340mcg / 12mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Duaklir Genuair 340 micrograms /12 micrograms inhalation powder?

The active substance in Duaklir Genuair 340 micrograms /12 micrograms inhalation powder is aclidinium bromide, formoterol fumarate dihydrate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Duaklir Genuair 340 micrograms /12 micrograms inhalation powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Duaklir Genuair 340 micrograms /12 micrograms inhalation powder without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

  • Source: electronic medicines compendium (emc), Datapharm
  • Active substance: aclidinium bromide, formoterol fumarate dihydrate
  • Official document: view the original leaflet on emc →
Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Aclidinium bromide (2 medicines), Aclidinium bromide, formoterol fumarate dihydrate (1 medicine), Formoterol fumarate dihydrate (37 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

4.2. Posology and method of administration

Posology

The recommended dose is one inhalation twice daily.

If a dose is missed, it should be taken as soon as possible and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.

Elderly

No dose adjustments are required in elderly patients (see section 5.2).

Renal impairment

No dose adjustments are required in patients with renal impairment (see section 5.2).

Hepatic impairment

No dose adjustments are required in patients with hepatic impairment (see section 5.2).

Paediatric population

There is no relevant use of Duaklir Genuair in children and adolescents (under 18 years of age) for the indication of COPD.

Method of administration

For inhalation use.

Patients should be instructed on how to administer the product correctly as the Genuair inhaler may work differently from inhalers the patients may have used previously. It is important to instruct the patients to read the Instructions for Use in the Package Leaflet.

Before first use, the sealed bag should be teared open, and the inhaler removed. The bag and the desiccant should be thrown away.

For instructions for use, see section 6.6.

4.3. Contraindications

Hypersensitivity to the active substances or to the excipient listed in section 6.1.

4.4. Special warnings and precautions for use

Asthma

Duaklir Genuair should not be used in asthma; clinical studies of Duaklir Genuair in asthma have not been conducted.

Paradoxical bronchospasm

In clinical studies, paradoxical bronchospasm was not observed with Duaklir Genuair at its recommended dose. However, paradoxical bronchospasm has been observed with other inhalation therapies. If this occurs, medicinal product should be stopped and other treatment will be considered.

Not for acute use

Duaklir Genuair is not indicated for the treatment of acute episodes of bronchospasm.

Cardiovascular effects

β2-adrenergic agonists may produce increases in pulse rate and blood pressure, electrocardiogram (ECG) changes such as T wave flattening, ST segment depression and prolongation of the QTc-interval in some patients. In case such effects occur, treatment may need to be discontinued. Long-acting β2-adrenergic agonists should be used with caution in patients with history of or known prolongation of the QTc-interval or treated with medicinal products affecting the QTc interval (see section 4.5).

Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia were seen after the administration of Duaklir Genuair (see section 4.8). Therefore, Duaklir Genuair should be used with caution in patients with cardiac arrhythmias, a history of cardiac arrhythmias or with risk factors for cardiac arrhythmias.

Systemic effects

Duaklir Genuair should be used with caution in patients with severe cardiovascular disorders, convulsive disorders, thyrotoxicosis and phaeochromocytoma.

Metabolic effects of hyperglycaemia and hypokalaemia may be observed with high doses of β2‑adrenergic agonists. In Phase III clinical studies, the frequency of notable increases in blood glucose with Duaklir Genuair was low (0.1%) and similar to placebo. Hypokalaemia is usually transient, not requiring supplementation. In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (see section 4.5). Hypokalaemia increases susceptibility to cardiac arrhythmias.

Due to its anticholinergic activity, Duaklir Genuair should be used with caution in patients with symptomatic prostatic hyperplasia, urinary retention or narrow-angle glaucoma (even though direct contact of the product with the eyes is very unlikely). Dry mouth, which has been observed with anticholinergic treatment, may in the long term be associated with dental caries.

Lactose content

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5. Interaction with other medicinal products and other forms of interaction

COPD medicinal products

Co-administration of Duaklir Genuair with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended.

Although no formal in vivo drug interaction studies have been performed with Duaklir Genuair, it has been used concomitantly with other COPD medicinal products including short-acting β2-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids without clinical evidence of drug interactions.

Hypokalaemic treatment

Concomitant treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of β2-adrenergic agonists, therefore caution is advised in their concomitant use (see section 4.4).

β-adrenergic blockers

β-adrenergic blockers may weaken or antagonise the effect of β2-adrenergic agonists. If β-adrenergic blockers are required (including eye drops), cardioselective beta-adrenergic blockers are preferred, although they should also be administered with caution.

Other pharmacodynamic interactions

Duaklir Genuair should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval such as monoamine oxidase inhibitors, tricyclic antidepressants, antihistamines or macrolides because the action of formoterol, a component of Duaklir Genuair, on the cardiovascular system may be potentiated by these medicinal products. Medicinal products that are known to prolong the QTc interval are associated with an increased risk of ventricular arrhythmias.

Metabolic interactions

In vitro studies have shown that aclidinium or its metabolites at the therapeutic dose are not expected to cause interactions with P-glycoprotein (P-gp) substrate drugs or drugs metabolised by cytochrome P450 (CYP450) enzymes and esterases. Formoterol does not inhibit the CYP450 enzymes at therapeutically relevant concentrations (see section 5.2).

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no data available on the use of Duaklir Genuair in pregnant women.

Studies in animals have shown foetotoxicity only at dose levels much higher than the maximum human exposure to aclidinium and adverse effects in reproduction studies with formoterol at very high systemic exposure levels (see section 5.3).

Duaklir Genuair should only be used during pregnancy if the expected benefits outweigh the potential risks.

Breast-feeding

It is unknown whether aclidinium (and/or its metabolites) or formoterol are excreted in human milk. As studies in rats have shown excretion of small amounts of aclidinium (and/or its metabolites) and formoterol into milk, the use of Duaklir Genuair by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant.

Fertility

Studies in rats have shown slight reductions in fertility only at dose levels much higher than the maximum human exposure to aclidinium and formoterol (see section 5.3). Nevertheless, it is considered unlikely that Duaklir Genuair administered at the recommended dose will affect fertility in humans.

4.7. Effects on ability to drive and use machines

Duaklir Genuair has no or negligible influence on the ability to drive and use machines. The occurrence of blurred vision or dizziness may influence the ability to drive or to use machines.

4.8. Undesirable effects

The presentation of the safety profile is based on the experience with Duaklir Genuair and the individual components.

Summary of the safety profile

The safety experience with Duaklir Genuair comprised exposure in clinical trials at the recommended therapeutic dose for up to 12 months, and in post-marketing experience.

Adverse reactions associated with Duaklir Genuair were similar to those of the individual components. As Duaklir Genuair contains aclidinium and formoterol, the type and severity of adverse reactions associated with each of the components may be expected with Duaklir Genuair.

The most frequently reported adverse reactions with Duaklir Genuair were nasopharyngitis (7.9%) and headache (6.8%).

Tabulated summary of adverse reactions

The Duaklir Genuair clinical development programme was conducted in patients with moderate or severe COPD. A total of 1222 patients were treated with Duaklir Genuair 340 micrograms /12 micrograms. The frequencies assigned to the adverse reactions are based on crude incidence rates observed with Duaklir Genuair 340 micrograms /12 micrograms in the pooled analysis of randomised, placebo-controlled Phase III clinical studies of at least six months duration, or on experience with individual components or on post-marketing study results.

The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).

System organ class

Preferred term

Frequency

Infectious and infestations

NasopharyngitisUrinary tract infectionSinusitisTooth abscess

Common

Immune system disorders

Hypersensitivity

Rare

Angioedema

Anaphylactic reaction

Not known

Metabolism and nutrition disorders

Hypokalaemia

Uncommon

Hyperglycaemia

Uncommon

Psychiatric disorders

InsomniaAnxiety

Common

Agitation

Uncommon

Nervous system disorders

Headache

Dizziness

Tremor

Common

Dysgeusia

Uncommon

Eye disorders

Blurred vision

Uncommon

Cardiac disorders

Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia

TachycardiaElectrocardiogram QTc prolongedPalpitations

Angina pectoris

Uncommon

Respiratory, Thoracic and mediastinal disorders

Cough

Common

Dysphonia

Throat irritation

Uncommon

Bronchospasm, including paradoxical

Rare

Gastrointestinal disorders

Diarrhoea

Nausea

Dry mouth

Common

Stomatitis

Uncommon

Skin and subcutaneous tissue disorders

Rash

Pruritus

Uncommon

Musculoskeletal and connective tissue disorders

Myalgia

Muscle spasms

Common

Renal and urinary disorders

Urinary retention

Uncommon

Investigations

Blood creatine phosphokinase increased

Common

Blood pressure increased

Uncommon

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

There is limited evidence on the management of overdose with Duaklir Genuair. High doses of Duaklir Genuair may lead to exaggerated anticholinergic and/or β2-adrenergic signs and symptoms; the most frequent of which include blurred vision, dry mouth, nausea, muscle spasm, tremor, headache, palpitations and hypertension.

Duaklir Genuair should be discontinued in case of overdose. Supportive and symptomatic treatment is indicated.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

⚠ Not the same combination. This medicine contains Aclidinium bromide, Formoterol fumarate dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • ATIMOS 0,012mg/doza prescription partial — not the same combinationFORMOTEROLUM · inhaler / nebuliser
  • BRIMICA GENUAIR 340 micrograme/12 micrograme prescription partial — not the same combinationACLIDINIUM BROMIDUM+FORMOTEROLUM FUMARAT · inhaler / nebuliser
  • DUAKLIR GENUAIR 340 micrograme/12 micrograme prescription partial — not the same combinationACLIDINIUM BROMIDUM+FORMOTEROLUM FUMARAT · inhaler / nebuliser

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • Brimica GenuairAclidinium + Formoteroli fumaras · inhaler / nebuliser
  • Duaklir GenuairAclidinium + Formoteroli fumaras · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Duaklir Genuair 340 micrograms /12 micrograms inhalation powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →